Pharming

Company Overview

Pharming Group N.V. is a biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. Founded in 1988 in Leiden, Netherlands, the company has evolved from its pioneering work with recombinant protein technology to become a leading player in rare disease therapeutics. Pharming reported full-year 2025 revenue of $317.9 million, representing significant growth and profitability. The company operates with a hybrid business model combining orphan drug market focus with clinical precision, international reach, and a patient-first culture, enabling it to address significant unmet medical needs in rare disease populations.

Headquarters and Global Presence

Pharming Group is headquartered in Leiden, the Netherlands, with U.S. headquarters located in Warren, New Jersey. The company maintains a global footprint to support research, development, and commercial operations across multiple regions. Pharming is publicly traded on Euronext Amsterdam under the ticker PHARM and on Nasdaq Global Select Market under the ticker PHAR, providing access to both European and North American capital markets.

Founding and History

Pharming Group was established on November 11, 1988, as Genfarm B.V., a Dutch biotechnology firm pioneering innovative approaches to protein production. The company created Herman, the first genetically engineered bull, whose offspring produced human proteins in their milk—a breakthrough technology subsequently extended to rabbits. This platform enabled Pharming to purify human proteins for treating blood disorders, transplant complications, and injuries, establishing the technical foundation for its current drug development pipeline. The company evolved from this foundational technology into a publicly-held biopharmaceutical enterprise focused on rare disease therapeutics.

Therapy Areas and Focus

Pharming concentrates on rare disease areas with significant unmet medical needs, with primary therapeutic focus on immunological disorders, particularly hereditary angioedema and primary immunodeficiencies linked to PI3K signaling. The company also actively develops therapies for mitochondrial diseases, recognized as an emerging area with blockbuster potential. These focused therapy areas allow Pharming to leverage deep scientific expertise and maintain close engagement with patient communities, enabling more efficient clinical development and faster pathway to commercialization.

Technology Platforms and Modalities

Pharming employs multiple therapeutic modalities including protein replacement therapies, small molecule kinase inhibitors, and gene therapy approaches. The company's legacy platform involves recombinant human proteins produced through innovative manufacturing processes. Current pipeline assets demonstrate Pharming's capability in precision medicine, utilizing targeted small molecules to address specific genetic dysregulation pathways. The company also pursues gene therapy development through strategic partnerships, expanding its therapeutic toolkit to address various rare disease mechanisms.

Key Pipeline and Programs

Pharming's commercial portfolio includes Ruconest (recombinant human C1 inhibitor), a protein replacement therapy for hereditary angioedema that continues to generate significant revenue, and Joenja (leniolisib), a small molecule kinase inhibitor approved for activated PI3K delta syndrome that is driving accelerating growth. The company is advancing leniolisib into Phase II proof-of-concept trials in primary immunodeficiencies, with top-line data expected in the second half of 2026. Additionally, Pharming acquired Swedish biotech Abliva for $66 million to obtain napazimone (KL1333), a pivotal-stage candidate for mitochondrial disease with perceived blockbuster potential. The company guides 2026 total revenues between $405 million and $425 million, with expanded research and development spending supporting the napazimone FALCON trial and continued leniolisib Phase II advancement.

Key Personnel

Fabrice Chouraqui serves as Chief Executive Officer and Executive Director, appointed in March 2025 for a four-year term. Chouraqui brings extensive pharmaceutical leadership experience from Flagship Pioneering, Novartis, and Bristol-Myers Squibb across research and development, commercialization, and business development. Richard Peters serves as Chairman, with prior roles as Global Head of Rare Diseases at Sanofi Genzyme and Chief Executive Officer of Yumanity Therapeutics and Merrimack Pharmaceuticals. Ines Bernal has served as Chief People Officer since December 2024, bringing human resources expertise from Celanese Corporation. Sijmen de Vries, the previous CEO, remains available as a strategic advisor through December 31, 2025.

Strategic Partnerships

Pharming pursues a disciplined in-licensing and acquisition strategy aligned with its rare disease focus. The company licensed Joenja from Novartis, a strategic partnership that brought precision medicine capabilities into its commercial portfolio. Pharming collaborates with Sanofi and BioConnection for manufacturing and supply chain processes. The company developed OTL-105, a gene therapy for hereditary angioedema, through collaboration with Orchard Therapeutics, expanding its therapeutic modalities. Pharming also partnered with Equals 5 to launch educational initiatives for healthcare professionals regarding APDS awareness. Additionally, the company collaborates with Genomenon to provide clinicians and genetic testing laboratories access to comprehensive PIK3CD and PIK3R1 variant data through the Mastermind platform, supporting precision diagnostic capabilities.

FAQ Section